Dr. Jothydev Kesavadev was an invited faculty at the launch of Rybelsus (Semaglutide) in India, at the �Innovate 2022�, held in association with Indo Global Cardio Diabetes Academy and Novo Nordisk, on 15 January 2022. The program included 2 plenary sessions, chaired by Dr. V. Mohan and involved 3-panel discussions. Dr. Jothydev Kesavadev was a panellist for the panel discussion �Innovation: An ongoing saga in Diabetes�.